Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged Non-Small Cell Lung Cancer with brain metastases

In-frame fusion KIF5B (the-kinesin-family-5B-gene)-RET transcripts have been characterized in 1–2% of non-small cell lung cancers and are known oncogenic drivers. The RET tyrosine kinase inhibitor, vandetanib, suppresses fusion-induced, anchorage-independent growth activity. In vitro studies have sh...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Lung Cancer
Main Authors: Subbiah, Vivek, Berry, Jenny, Roxas, Michael, Guha-Thakurta, Nandita, Subbiah, Ishwaria Mohan, Ali, Siraj M., McMahon, Caitlin, Miller, Vincent, Cascone, Tina, Pai, Shobha, Tang, Zhenya, Heymach, John V.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998046/
https://ncbi.nlm.nih.gov/pubmed/25982012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2015.04.004
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki